Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), announced its launch of Doxycycline Capsules, 40 mg* in the U.S. market, a therapeutic generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy's Doxycycline Capsules, 40 mg*, are supplied in bottle counts of 30.

*Each capsule contains: 26 mg immediate-release pellets and 14 mg delayed-release pellets equivalent to 40 mg of anhydrous doxycycline, USP.

ORACEA® is a trademark of Galderma Holdings, S.A.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 6349.95 as compared to the previous close of Rs. 6288.30. The total number of shares traded during the day was 28428 in over 4944 trades.

The stock hit an intraday high of Rs. 6420.00 and intraday low of 6260.00. The net turnover during the day was Rs. 180463879.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY DoxycyclineCapsules USMarket